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INTRODUCTION
MicroRNAs are small, non-coding
RNAs of 18 to 24 nucleotides, discovered
in 1993 in the nematode Caenorhabditis el-
egans. Lee et al. [2] found that a gene cru-
cial for C. elegans post-embryonic
development, lin-4, does not code for a pro-
tein, but rather is transcribed into a 22-nu-
cleotide RNA molecule. This molecule
could repress the expression of the lin-14
mRNA by directly interacting with its 3’
untranslated region (UTR) [3]. While this
was recognized as a new method of gene
regulation, it was initially considered as an
oddity peculiar to C. elegans. The discov-
ery of let-7, another small RNAinvolved in
developmental timing in C. elegans [4],
and the finding that both its sequence and
temporal expression pattern were largely
conserved in a variety of organisms [5] im-
mediately suggested these small RNAs
might in fact play important and conserved
roles in gene regulation, and the identifica-
tion of hundreds of miRNAs in the worm,
fly, and mammalian genomes followed [1].
To date, more than 300 miRNAs have
been discovered in humans, and computa-
tional analyses predict that up to 1,000
miRNAs exist in the genome [6,7]. Since
miRNAs can regulate more than one target,
estimates indicate they may be able to reg-
ulate up to 30 percent of the protein-coding
genes in the human genome [8], highlight-
ing their importance as global regulators of
gene expression.
miRNA BIOGENESIS AND
METHOD OF ACTION
MiRNAs are transcribed by RNA
Polymerase II into large precursor RNAs,
often several kilobases in length, called pri-
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Cancer is a complex and dynamic disease, involving a variety of changes in gene expression
and structure. Traditionally, the study of cancer has focused on protein-coding genes, con-
sidering these as the principal effectors and regulators of tumorigenesis. Recent advances,
however, have brought non-protein-coding RNA into the spotlight. MicroRNAs (miRNAs)†,
one such class of non-coding RNAs, have been implicated in the regulation of cell growth,
differentiation, and apoptosis [1]. While their study is still at an early stage, and their mech-
anism of action along with their importance in cancer is not yet fully understood, they may
provide an important layer of genetic regulation in tumorigenesis, and ultimately become
valuable therapeutic tools.
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In the nucleus, these pri-miRNAs are
capped and polyadenylated prior to being
processed by Drosha, a member of the
RNase III enzyme family, in conjunction
with the double-stranded RNA-binding pro-
tein DGCR8/Pasha. This processing step
produces segments ~70 nucleotides in
length, which fold into stem-loop structures
known as pre-miRNAs [9]. These are ex-
ported from the nucleus in a GTP-dependent
fashion by exportin 5 and are subject to an
additional processing step by another RNase
III enzyme, Dicer. This step releases a dou-
ble-stranded RNA duplex, ~22 nucleotides
in length, which in turn is incorporated into
the miRISC complex, in analogous fashion
to that observed in RNA interference
(RNAi). In this complex, the mature miRNA
strand is retained, and the complex is now
capable of regulating its target genes.
The identification of miRNA target
transcripts remains one of the greatest chal-
lenges in the field today. MiRNAs can be or-
ganized into families based on sequence
homology, which is particularly strong at the
5’end of the mature miRNA, suggesting this
section of the mature transcript has been pre-
served through evolution and thus plays an
important role in the process of target recog-
nition. Indeed, studies have shown this 5’re-
gion, often called the “miRNA seed,” to be
crucial for both the stability of the mature
miRNA and its incorporation into the
miRISC complex [10-14]. Bioinformatic ap-
proaches have taken advantage of this
“miRNA seed” to predict miRNA targets
across the genome. It has been predicted that
a single miRNAcan bind over 200 different
target transcripts, and, notably, these targets
are highly diverse, from transcription factors
to transporters [15-24].
There is nevertheless evidence support-
ing a role for the regions not encompassed
within the “miRNAseed.” Perhaps the clear-
est example of this is found in let-7, whose
complete mature miRNA sequence is con-
served across species [25], suggesting an
important role for the 3’ region of the
miRNAin target transcript binding. Further
insights into the miRNA-target recognition
mechanism are needed, as they will make
target prediction much more accurate and ef-
ficient.
A POTENTIAL ROLE FOR miRNAS
IN CANCER
Cancers of all types share a number of
characteristics, such as the loss of cellular
identity, an increased ability to grow and
proliferate, and alterations in the systems
controlling cell death. Studies performed in
a variety of organisms have revealed that
miRNAs have the ability to regulate these
cellular processes, suggesting that they
could be involved in cancer. For instance,
lin-4 and let-7 control the timing of devel-
opmental events in C. elegans. Mutations in
these miRNAs resulted in abnormalities in
cell-cycle exit as well as in the execution of
a terminal differentiation program, prevent-
ing cells from reaching their fully differen-
tiated state [2].
In Drosophila, it has been found that
over-expression of the Bantam miRNA
causes excessive growth of wing and eye tis-
sue by blocking the pro-apoptotic action of
the gene hid [26, 27]. It was also found that
another Drosophila miRNA, miR-14, can
act as a strong suppressor of apoptosis.
Deletion of this miRNA caused increased
expression of the apoptotic effector caspase,
Drice, suggesting a direct regulation of this
factor by miR-14 [28]. Likewise, the
miR-2/6/11/13/308 family of Drosophila
miRNAs has been reported to induce wide-
spread apoptosis in embryos through the
regulation of the proapoptotic factors hid,
grim, reaper, and sickle, which act through
the inhibition the caspase inhibitor Diap1 in
response to a number of natural and toxic
conditions [29].
Another aspect in which miRNAs ap-
pear to have a role is the proper differentia-
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ple, miR-273 and the miRNA encoded by
lys-6 have been shown to play important
roles in the patterning of the C. elegans
nervous system [30,31], and miR-430 has
been implicated in brain development [3].
The importance of miRNA in development
has been shown also in mammalian systems,
examples of which are miR-181 in the dif-
ferentiation of hematopoietic cells toward
the B-cell lineage [33], miR-374 in pancre-
atic islet-cell development [34], miR-143 in
adipocyte differentiation [35], miR-196 in
limb patterning by SHH [36], and miR-1 in
heart development [37].
miRNAS AS TUMOR SUPPRESSORS
miR-15a and miR-16-1 in CLL
The first study directly suggesting that
dysregulationofmiRNAplayedanimportant
roleformiRNAsintumorigenesiscamefrom
Calin et al. [38] It was known that loss of
chromosomal region 13q14 was strongly as-
sociated with B cell chronic lymphocytic
leukemia (CLL), the most common form of
leukemia in the Western hemisphere; how-
ever, no gene or genes had been definitely di-
rectly linked with CLL. After refining the
critical region within 13q14 to about 30kb,
Calin et al. failed to identify any protein cod-
ing genes but recognized that two miRNAs,
miR-15aandmiR-16-1,wereclusteredwithin
this chromosomal locus. Indeed, expression
ofthesemiRNAswasfoundtobediminished
or completely ablated in > 65 percent of CLL
cases examined. Further studies revealed a
germline C-to-T mutation seven base pairs
downstream of the miR-16-1 hairpin in two
outof75CLLpatients.Thismutationwasnot
found in any of 160 control individuals. Be-
causethemechanismsformiRNAbiogenesis
arenotyetfullyunderstood,itisunclearwhat
thepreciseeffectofthismutationis;however,
itwasfoundthatthemutationcorrelatedwith
diminished expression of this miRNA in pa-
tient-derived CLLcells, while preventing the
processingofthemiRNAintoitsmatureform
when expressed in heterologous cell systems
[39].
The common loss of miR-15a and miR-
16-1 in CLL, as well as the loss of 13q14 in
mantle cell lymphoma (50 percent of cases),
multiple myeloma (16 to 40 percent) and
prostatecancer(60percent)[38,40],strongly
suggeststhatthesetwomiRNAsactastumor
suppressor genes. While their full target
complement is unknown, they appear to me-
diatetheireffectslargelybydown-regulating
theanti-apoptoticproteinBCL2.Thisprotein
is often found expressed at high levels in
CLL and is thought to be important for the
survival of the malignant cells [41]. Consis-
tent with a role for these miRNAs in the
down-regulation of BCL2, loss of
miR-15a and miR-16-1 correlates with ele-
vatedlevelsofBCL2,whileheterologousex-
pression of these miRNAs results in
decreased levels of the endogenous proteins
[42]. The 3’UTR of the Bcl2 transcript has
been found to contain binding sites for
miR-15a and miR-16-1, and reporter con-
structscontainingtheBcl23’UTRaredown-
regulated upon co-expression with miR-15a
andmiR-16-1.Moreover,expressionofthese
miRNAs is capable of inducing apoptosis in
a leukemia cell line. Further research is nec-
essary to better evaluate whether miR-15a
and miR-16-1 exert their effects mainly
throughBCL2ortargetadditionaltranscripts
in CLL. Nonetheless, the evidence available
supports an important role for miR-15a and
miR-16-1 in the prevention of lymphomage-
nesis and leukaemogenesis.
The let-7 family can negatively regulate Ras
As noted earlier, the miRNAs of the let-
7 family were among the first to be de-
scribed, and experiments performed in
C. elegans provided the first indication that
they may be involved in cancer. Early stud-
ies showed that loss-of-function let-7 mu-
tants were defective in the transition from
late larval to adult stage. Upregulation of let-
7 in adult seam cells, on the other hand, is
necessary to induce cell-cycle exit and ter-
minal differentiation. If this miRNA is ab-
sent, these cells fail to differentiate,
undergoing additional rounds of division, a
phenomenon often observed in cancer cells
[43].
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human genome, organized in eight clusters.
These clusters map to fragile sites associated
with lung, breast, urothelial, and cervical
cancers, suggesting that let-7 family mem-
bers may act as tumor suppressors. At least
four of these clusters have been confirmed
to be commonly lost in malignancies [44].
Studies by Takamizawa et al. andYanaihara
et al. have presented evidence that tran-
scripts of certain let-7 homologs are signif-
icantly downregulated in human lung cancer
and that low levels of let-7 correlate with
poor prognosis [45,46]. Moreover, it has
been shown that transient expression of
miRNAs of the let-7 family in cell lines de-
rived from lung adenocarcinomas inhibited
colony formation, suggesting that these
miRNAs could have growth-suppressing
properties and opening the possibility that
let-7 might be used as a therapeutic tool.
Important insights into the mechanism
through which let-7 is capable of controlling
cellular proliferation came from our labora-
tory, derived from the observation that the
let-7 family member miR-84 negatively reg-
ulates let-60, the ortholog of human HRAS,
KRAS, and NRAS in C. elegans [47]. We
have shown that certain members of the let-
7 family are capable of genetically interact-
ing with RAS, and let-7 and RAS are
reciprocally expressed in lung tumor sam-
ples. We also found that let-7 is capable of
negatively regulating RAS in human cells,
and overexpression of let-7 in human cancer
cell lines results in reduced levels of RAS
protein, compared to untreated cells.As ex-
pected, if let-7 levels are reduced in cancer
cell lines, levels of RAS protein increase sig-
nificantly. Moreover, through the use of re-
porter constructs, it was confirmed that the
regulation of RAS by let-7 takes place
through the direct interaction of the miRNA
with the 3’UTR of Ras mRNA.
The human RAS family of proteins is
one of the most important components of a
myriad of signaling cascades, has been
shown to possess oncogenic activity, and is
often mutated in tumors [48].As such, these
studies position let-7 as a promising thera-
peutic tool for the treatment of lung cancer,
as well as other malignancies resulting from
the overexpression of RAS. It will be impor-
tant to more carefully analyze the specific
contributions of the individual members of
this miRNAfamily, in order to better under-
stand the let-7-mediated regulation of cell
growth.
Other miRNAs acting as tumor suppressors
Studies have implicated other miRNAs
in tumorigenesis. MiR-143 and miR-145,
for instance, have been shown to be con-
stantly down-regulated in colorectal tumors
[49], and recent studies by Croce et al. also
have shown that the downregulation of these
miRNAs is a common occurrence in breast
carcinomas and breast cancer lines [50].
Moreover, the location of these miRNAs is
known to be in a genomic locus frequently
deleted in myelodysplastic syndrome [44].
While some studies have ascribed the down-
regulation of miR-143 and miR-145 in colon
cancer to a block in Dicer processing [49],
further studies are required to determine
whether the expression levels of these
miRNAs are specifically altered.
miRNAS AS ONCOGENES
Several microRNAs may regulate MYC in a
dynamic manner
MicroRNAs can also act as oncogenes,
either directly by down-regulating tumor
suppressors or indirectly by down-regulat-
ing genes that can act to restrict the activity
of known oncogenes. An example of this is
found in the dynamics of the interaction be-
tween miR-155 and the MYC oncogene, a
transcription factor with the ability to regu-
late cell growth through the induction of
both cell proliferation and apoptosis [51].
Notably, MYC is often mutated or amplified
in human cancers.The miRNAmiR-155 has
been linked with MYC overexpression and
B-cell cancers, suggesting it may be playing
a role in the regulation of this oncogene.
miR-155 is encoded by nucleotides
241-262 of BIC, which was originally iden-
tified as a transcript derived from an integra-
tion site for the avian leukosis virus and
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phomas [52,53]. The understanding of how
BIC might mediate its effects was limited for
several years, as it remained unclear how a
presumably non-protein-coding RNA with
little overall conservation among avian,
murine, and human genomes could consis-
tently produce lymphomas and induce the
overexpression of MYC. Metzler et al. ana-
lyzed the phylogenetically conserved re-
gions in BIC and found that the highest
homology was located in a 138 nucleotide
section of the gene, which in fact encoded
the pri-miRNA for miR-155 [54]. Subse-
quent studies showed that miR-155 expres-
sion is upregulated 100-fold in pediatric
Burkitt lymphoma, as well as in Hodgkin’s
lymphoma and primary mediastinal and cer-
tain subsets of large-B cell lymphomas [55,
56,56].The role of miR-155 is not restricted
to B cell lymphomas, however. Recent stud-
ies have reported that miR-155 is upregu-
lated in breast, lung, colon, and thyroid
cancers [57-59]. It has also been reported
that mice overexpressing miR-155 under the
control of the Eﾵ enhancer rapidly develop
B-cell malignancy, underscoring the ability
of miR-155 to induce lymphomagenesis
without the requirement for other major ge-
netic changes, strongly suggesting miR-155
can act as a bona fide oncogene [60]. Never-
theless, the mechanism of action of miR-155
is unknown, stressing the need for further
study of this miRNA.
The interaction with MYC is not exclu-
sive to miR-155. Recent studies have de-
scribed the relationship between MYC,
cancer,andthe13q31locus[61,62].Thisge-
nomic locus is amplified in a number of can-
cers, such as diffuse large-B-cell lymphoma,
follicular lymphoma, mantle cell lymphoma,
and primary cutaneous B-cell lymphoma.
However,theonlygeneoverexpressedinthis
amplicon is a non-protein-coding RNA,
C13orf25 [63], which has been shown to en-
codethemiR-17-92cluster,containingseven
miRNAs: miR-17-5p, miR-17-3p, miR-18a,
miR-19a,miR-20a,miR-19b-1,andmiR-92-
1.Heetal.haveshownthatcelllinescarrying
anamplificationof13q31wereanalyzed,and
it was found that six miRNAs had increased
expression, five of which belonged to the
miR-17-92 cluster [61]. Furthermore, it was
also shown that the pri-miRNA for the
miR-17-92clusterwasupregulatedin65per-
cent of the tested B cell lymphoma samples.
Thesedatasuggestedadirectinvolvementof
this miRNAcluster in tumorigenesis.
Further indication of the involvement of
the miR-17-92 cluster in cancer was found
in subsequent experiments, in which the
miR-17-19b-1 cluster (the vertebrate-spe-
cific segment of the miR-17-92 cluster) was
overexpressed using a retroviral system in
hematopoietic stem cells (HSCs) from mice
carrying the Myc transgene. Lethally irradi-
ated animals which received HSCs express-
ing both miR-17-19b-1 cluster and Myc
developed malignant lymphomas more rap-
idly than those receiving HSCs expressing
Myc alone. The lymphomas from mice ex-
pressing both Myc and miR-17-19b-1 were
characterized by increased cell proliferation
and decreased apoptosis levels, when com-
pared to the malignancies arising from the
mice receiving HSCs with Myc alone. Com-
plementary experiments showed that this ef-
fect is exclusive to the miRNAs of the
miR-17-19b-1 cluster and any one individual
miRNA from this cluster is unable to cause
accelerated lymphomagenesis. Together,
these results suggest that the miRNAs com-
posing the miR-17-19b-1 act cooperatively
as oncogenes, presumably by targeting
proapoptotic and anti-proliferative factors.
Independently, O’Donnell et al. identi-
fied the miR-17-92 cluster as a group of po-
tentially cancer-related genes through
microarray analysis of a set of human,
mouse, and rat miRNAs to identify miRNAs
with altered levels in a human B-cell line
that overexpresses MYC [62]. It was found
that MYC induced the expression of the
miR-17-92 cluster. Moreover, chromatin im-
munoprecipitation experiments confirm this
interaction by establishing that MYC binds
within the first intronic region of C13orf25,
suggesting that MYC has the ability to di-
rectly regulate the miR-17-92 cluster.
An intriguing scenario was suggested
by the bioinformatic prediction that the
members of the miR-17-92 cluster, miR-17-
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tor E2F1. E2F1 regulates the transition from
G1 to S phase of the cell cycle by regulating
genes that are involved in DNAreplication,
cell division, and apoptosis [64]. Notably,
E2F1 is known to function in a reciprocal
positive-feedback loop with MYC. Consis-
tent with this, it was found that inhibition of
miR-17-5 and miR-20a in a cervical cancer-
derived cell line resulted in a concomitant
increase in the expression level of E2F1.
Likewise, mutations of the sites complemen-
tary to miR-17-5p and miR-20a in the
3’UTR of E2F1 resulted in increased re-
porter activity, compared with that of con-
structs harboring the wild-type sequence of
E2F1’s 3’UTR. These results suggest a
model in which MYC can induce the tran-
scription of both the miR-17-92 cluster and
E2F1; in turn, the miRNAs of the cluster
negatively regulate the transcription of
E2F1. One consequence of this model is that
miRNAs of the miR-17-92 cluster directly
regulate the effector of MYC-mediated cell
growth.
An apparent paradox, however, also
emerges from these results. In the presence of
MYC, as noted above, the miR-17-92 cluster
wouldfunctionasatumorsuppressor,curbing
thecellulargrowthmediatedbyE2F1,whichis
incontradictionwiththeresultsofHeetal.that
implicated miR-17-92 as an oncogene. These
results can perhaps be reconciled by consider-
ing that while E2F1 can promote cellular pro-
liferation,ithasbeenreportedthatitspresence
in excess levels can induce apoptosis [64].As
such, the negative regulation of E2F1 by the
miRNAsofthemiR-17-92clustermightinfact
prevent E2F1 levels from reaching the thresh-
oldatwhichapoptosisistriggered,thusacting
asanoncogenebysupportingMYC-mediated
proliferation.
ItisclearthattheinteractionofmiRNAs
with their targets is not as straightforward as
initialstudiesmighthavesuggestedandintri-
cate regulatory networks are in place for any
one cellular system. There exists the possi-
bility that the precise role of miR-17-92 in a
given cell depends on what other miRNAs
arepresent,whichinturnmaybeaffectedby
spatial and temporal considerations.
miRNA SIGNATURES AND
DETECTION METHODS
The multiple lines of evidence indicat-
ing that microRNAs are differentially ex-
pressed in normal and in tumor samples
suggest that miRNAs could serve as useful
tumor profiling tools. Indeed, profiling stud-
ies have shown that each cancer type pos-
sesses a distinct miRNA expression
signature, and this signature can provide
useful information about the malignancy.
The adaptation of high-throughput technolo-
gies have facilitated the study of the expres-
sion of multiple miRNAs in a given sample,
making it possible to profile substantial sam-
ple numbers with relative ease. Among the
most important methods for miRNA profil-
ing is the use of oligonucleotide miRNAmi-
croarray analysis, which allows the
researcher to simultaneously determine the
expression levels of hundreds of miRNAs in
a given sample [65-67]. Multiple variations
of this technique have been developed, un-
derscoring its position as the central miRNA
profiling tool [68-71]. Other important ap-
proaches to the problem are also available,
such as quantitative PCR for precursor
miRNAs [72] or mature miRNAs [73,74];
genome-wide approaches with serial analy-
sis of gene expression (SAGE), such as mi-
RAGE [75]; and bead-based flow
cytrometric techniques [76].
Taking advantage of these tools, several
groups have studied the miRNA expression
of several types of cancer. Michael et al. [49]
and Cummins et al. [75] have studied the ex-
pression profile of the known miRNAs in
colorectal cancer samples. These studies in-
dependently found a general down-regula-
tion of miRNA levels in tumor cells
compared to normal colonic epithelium,
while also observing a significant decrease
in the levels of miR-143 and miR-145 be-
yond this general effect. Cummins et al.
found a signature of 50 differentially ex-
pressed miRNAs in malignant vs. normal
colonic epithelium, of which 32 miRNAs
had reduced levels in tumor cells.Yanaihara
et al. studied over 100 patient-matched pairs
of primary malignant and normal adjacent
lung tissue and found that the expression of
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the tumor tissues compared to the normal
adjacent tissues. Of these miRNAs, 28 were
down-regulated and 15 were up-regulated in
the malignant tissue [46]. Similar studies
have been carried out in CLL [77], breast
cancer [50], glioblastoma [78], pancreatic
cancer [79], hepatocellular carcinoma [80],
and thyroid papillary carcinoma [58].
The ability to profile the miRNA ex-
pression of a tumor with accuracy and repro-
ducibility in a clinical setting would
constitute a valuable medical tool. Indeed,
miRNA profiles have been shown to be
highly informative. Using a bead-based ap-
proach, Lu et al. attempted to classify 17
poorly differentiated tumors with non-diag-
nostic histological appearance based on their
miRNAexpression profiles.Aclinical diag-
nosis on these tumors was established by
anatomical context, whether directly (a pri-
mary tumor observed in a given organ) or
indirectly (a metastasis of a previously iden-
tified primary tumor).They were able to cor-
rectly diagnose 12 of the 17 samples, against
1/17 correct diagnoses for an analysis using
their mRNAprofile [76]. While the number
of transcripts analyzed was much smaller for
miRNAs than for mRNAs (~200 against >
15,000), it is possible that the miRNA-based
diagnoses are more accurate because of the
regulatory role of these molecules, while
most mRNAs will not be regulatory in na-
ture. Further studies, however, are necessary
to ascertain the value of miRNAs as diag-
nostic tools, and their potential value as
prognostic markers, by correlating miRNA
expression with type-specific parameters
such as metastatic potential, proliferative
index, and response to existing treatments.
CLOSING REMARKS: miRNAS AS
TREATMENT TARGETS
While the field of miRNAs — and par-
ticularly the study of the roles of miRNAs
in cancer — is at an early stage, their poten-
tial as targeted therapeutic tools has not gone
unnoticed.Apromising approach is to target
oncogenic miRNAs with oligonucleotides
complementary for either their mature or
precursor sequence, deemed anti-miRNA
oligonucleotides (AMOs). A number of
chemical modifications for these oligonu-
cleotides are available, with the purpose of
making them more stable and less toxic. 2’-
O-methylated AMOs are perhaps the most
common form of modified RNA, conferring
limited nuclease resistance, and enhancing
the binding affinity to RNA. Inhibition of
let-7 function with 31-nucleotide
2’-O-Me AMOs has been demonstrated in
HeLa cells and C. elegans larvae [81], and
2’-O-MeAMOs have been reported to abro-
gate miRNA function in cellular assays
[82,83], providing proof-of-principle on the
blockage of miRNAfunction by extraneous
oligomers.Another common modification to
the structure of AMOs is that of the locked
nucleic acid (LNA)-modified oligomers. In
these RNAs, the 2’oxygen atom is linked to
the 4’ position through a methylene bridge,
forming a rigid bicyclic structure locked into
a C3’-endo (RNA) sugar conformation [84].
This modification results in greatly en-
hanced affinity for RNA and the formation
of exceedingly strong duplexes with excel-
lent mismatch discrimination properties [85-
87]. This makes them prime candidates for
AMO-based therapy, and results in rodents
have been encouraging [88].
While the use ofAMOs could be useful
to inhibit oncogenic miRNAs, another ther-
apeutic possibility concerns the cases in
which certain miRNAs are under-expressed,
such as let-7 in lung cancer, or miR-15a and
mir-16-1 in CLL. In this case, synthetic
miRNAs — likely modified as discussed
above — in either their mature or precursor
form could be delivered to the target cells to
counteract the deficiency and halt malignant
growth. While this approach has been at-
tempted in cell culture [89], further testing
in animal models is required.
A pressing challenge to the use of
miRNAs as therapeutic tools concerns find-
ing methods to deliver synthetic miRNAs or
AMOs to the desired tissues in a targeted
and effective manner. Given that these mol-
ecules cannot discriminate between healthy
and malignant cells, side effects of treatment
remain a concern. Likewise, since these
137 Espinosa and Slack: The Role of MicroRNAs in Cancerstudies are in their infancy, little is known
about the pharmacokinetics of AMOs or
synthetic miRNAs, limiting the discussion
of their promise as therapeutic tools into the
speculative arena. Upon reaching a deeper
understanding of the mechanism of miRNA
biogenesis and action, and the development
of new delivery technologies, these small
RNAs might well fulfill their promise as
valuable therapeutics.
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